News & insights
Research updates, company news, and perspectives on integrin biology and drug development.
Integrins are not simple on/off switches. Their conformational flexibility — and the allosteric sites that regulate it — is the foundation of AVIPERO's therapeutic approach.
Read moreWe are pleased to announce that our lead oncology program, AVP-101, has progressed into the lead optimisation stage following successful completion of hit identification activities.
The dominant paradigm in oncology has been cytotoxic: destroy the tumour. But what if we could guide malignant cells back to their normal state? That is the question AVIPERO was founded to answer.
Pulmonary fibrosis remains one of the most challenging diseases in respiratory medicine. Our AVP-202 program targets the αvβ6 integrin pathway that drives progressive fibrotic remodelling.
Sign up to receive AVIPERO Bio news and research updates.
